Antibody-based therapeutics currently enjoys exceptional success in the global biologic drug market. Achieving a total sale of nearly US$35 billion and holding six spots out of the top 20 best-selling pharmaceutical products in 2008, monoclonal antibodies (mAb) sales are predicted to grow exponentially to reach US$50 billion in 2013.

Rising research interest is further compelled by the large market potential that these substances may offer. Its ability to treat a wide range of complex diseases relating to oncology, inflammation and autoimmune diseases make the development of novel, proprietary antibodies top on every biopharmaceutical companies’ list. In addition, biosimilar antibodies on its own also represent a huge, multibillion-dollar opportunity for generic manufactures in the United States, Europe and Asia.

With the latest hype in biosimilar antibodies and promising success in developing bi-specific antibodies using new platform, the advancement in the field of therapeutic antibodies unravel more commercial opportunities and renewed optimism for the industry, making it an even more lucrative and dynamic market for investors.

Join us at IBC’s 4 th Annual Antibody Asia conference to learn about the latest antibody research and development, industry trends and updates and ways to expedite your antibody pipeline into revenue-generating biologics. Held from 20 th to 22 nd February in Shanghai, we promise to put together the most beneficial and multi-faceted agenda, delivered by internationally renowned speakers, specially catered to match your interest.

http://www.antibodiesasia.com/

The objective of this conference is to provide communication, education and networking opportunities for scientists engaged in Monoclonal Antibodies whether in academia, biotech or industry.Attendees will hear world-class speakers discussing the challenges and opportunities facing the Monoclonal Antibodies field.

http://www.biofind.com/events/monoclonal-antibodies-conference-march-13-14-2012-senate-house-london-uk

Mutations in the human genome are regarded as potentially disastrous events that lead to carcinogenesis. From the vantage point of B cell immunology, however, programmed DNA alterations at the antibody gene loci are essential for efficient antibody responses. A plethora of recent findings are beginning to illuminate open questions about the precise molecular mechanisms of these diversification processes, their regulation, and how errors in these pathways lead to cancer. Furthermore, the very same class of mutator enzymes plays an underappreciated role in non-lymphoid cancers, in antiviral responses and in epigenetic reprogramming. Antibody diversification not only shapes the repertoires of the immunological memory, but also those of auto-antibodies. The Keystone Symposia meeting on Mutations, Malignancy and Memory – Antibodies and Immunity will provide both a platform to integrate these more or less isolated fields and an opportunity to identify interfaces that could be relevant for therapeutic approaches in malignancies and autoimmune diseases.

http://www.keystonesymposia.org/meetings/viewMeetings.cfm?MeetingID=1162

This second Antibody Biology & Engineering GRC will provide this opportunity in a collegial and highly interactive environment that typifies the Gordon Research Conferences. Leading experts and thought leaders both from academia and industry will share their most recent findings on topics of broad interest to the attendees. Investigators and trainees at all levels will have many opportunities for presenting of their new, exciting results in poster sessions and selected oral presentations, with ample time for discussion, networking and brainstorming.

http://www.grc.org/programs.aspx?year=2012&program=antibody

International Congress of Antibodies is a premier conference, which aims to provide a forum for presentation of new research results and demonstration of new systems and techniques in the broad field of information technology and management. Information Technology supports varied organizations for the decision making. In the recent years antibody engineering and technology has came out as one of the mainstream biomedical areas; it plays a vital role in pharmaceutical and medical industries. International Congress of Antibodies will provide round table discussions to create network and marketing opportunities for expanding business. Young Scientist Forum will be also provided for the youngsters and new comers in the industry of science.

http://events.hellotrade.com/conferences/international-congress-of-antibodies/

More than 300 presentations covering science, technology, business, economics and policy in the field of antibodies by distinguished scientists and businessmen. Presentation of 200 posters and 100 exhibitions of new products and technologies to an audience of over 800 people. Round table discussions to create network and marketing opportunities for your business. Career fairs, poster sessions, expositions for both academia and industries. Tour to famous regions of China including Beijing and Xi'an

http://www.bitlifesciences.com/ica2012/fullprogram.asp

This focused partnering event provides greater depth of company coverage across a more narrow range of topics compared to typical partnering events. Presenting companies will be selected on the basis of competitive review of submitted proposals, as judged by the organizer and members of the Program Advisory Board, many of whom will also be participating in Panel Discussions at the beginning of each session of the program. Time is also provided for scheduling of one-on-one discussions, as well as networking time for unscheduled exploration of potential partnerships.

http://www.pegsummit.com/PEGS_C11.aspx?id=110391&libID=110348

The field of antibodies directed against cancer is burgeoning and this is a huge growth area due to the success of drugs already on the market.  There still remain a number of challenges that include reducing immunogenicity, improving the targeting in solid tumors, and increasing the ability to kill cancer cells.

The pre-clinical and clinical results of recent new constructs will be shared, and the changes in regulation of antibodies will be reviewed.  The latest new approaches will be compared to more established techniques for filling the pipeline with future best-in-class drugs.

http://www.pegsummit.com/cancer-antibodies

Therapeutic and diagnostic antibodies continue to make inroads in biomedicine, but the successful application of these products requires smart discovery and development.  This conference will explore the latest methods to overcome challenges and open new opportunities for making these valuable proteins viable.

http://www.pegsummit.com/engineering-antibodies

Bispecific and multiclonal antibodies are one of the most promising and exciting areas of protein engineering. Since 2009, there have been deals made in excess of $6.5 billion on bispecifics, and the range of therapeutic uses for bispecific antibodies are being expanding beyond oncology to diseases of the immune system, heart and CNS.

This meeting will explore the remaining challenges and profile creative problem solving that has been used to make successful bispecific formats.  The latest approaches for dual-targeting as well as targeting two different epitopes of the same receptor will be explored for improving efficacy.

http://www.pegsummit.com/bispecific-antibodies

The second stage of antibody therapeutic or diagnostic development can sometimes be the most difficult—the optimization.  This conference will present methods researchers can apply to make their antibody the best, most functional and least immunogenic it can be.

http://www.pegsummit.com/antibody-optimization

As demand increases, processes need to escalate in order to produce large numbers of purified antibodies.  Currently, between expression and purification, almost half of the product is lost.  Purification processes need to be improved to enhance recovery, while maintaining antibody quality.

The “Purifying Antibodies” meeting will feature leaders in the field who will share their case studies and experiences both innovating traditional purification techniques and also employing non-traditional approaches that show promising results.  The focus for the differing methods discussed will be “Streamlining Processes” with the aim of providing researchers a greater harvest.

http://www.pegsummit.com/purifying-antibodies

Antibody-drug conjugates (ADCs) in late-stage clinical development have shown encouraging therapeutic effects against both solid tumors and hematological malignancies. Significant progress has been made through optimization of parameters including specificity, potency, linker technology, conjugate site design, and the stoichiometry and placement of drugs.

These sessions will showcase the design and discovery of next generation ADC’s, leveraging current knowledge from successful clinical candidates.

http://www.pegsummit.com/antibody-drug-conjugates

The HAH 2012 scientific programme will include keynote lectures, contributed papers and poster presentations emphasising all key aspects of human antibody and hybridoma technology, applications and engineering.

http://www.meetingsmanagement.co.uk/index.php?option=com_content&view=article&id=26&Itemid=68